|
JP2806454B2
(ja)
|
1988-01-19 |
1998-09-30 |
武田薬品工業株式会社 |
脈管形成阻止剤
|
|
ES2053890T3
(es)
|
1988-09-01 |
1994-08-01 |
Takeda Chemical Industries Ltd |
Agente inhibidor de la angiogenesis.
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US9707302B2
(en)
*
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
JP4611441B2
(ja)
|
2006-04-03 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
|
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
KR20100102609A
(ko)
|
2007-11-12 |
2010-09-24 |
바이파 사이언스 인코포레이티드 |
Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
|
|
NZ586123A
(en)
|
2007-11-12 |
2012-12-21 |
Bipar Sciences Inc |
Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
|
|
JP5468015B2
(ja)
|
2008-01-08 |
2014-04-09 |
アクセリア ファーマシューティカルズ |
抗菌ペプチド系に対する作動薬
|
|
NZ586675A
(en)
|
2008-01-08 |
2012-04-27 |
Merck Sharp & Dohme |
Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010091140A1
(en)
|
2009-02-04 |
2010-08-12 |
Bipar Sciences, Inc. |
Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
|
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
WO2011153383A1
(en)
|
2010-06-04 |
2011-12-08 |
Bipar Science, Inc. |
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
|
|
WO2011160063A2
(en)
|
2010-06-18 |
2011-12-22 |
Myriad Genetics, Inc. |
Methods and materials for assessing loss of heterozygosity
|
|
ES2704303T3
(es)
|
2010-08-24 |
2019-03-15 |
Dana Farber Cancer Inst Inc |
Procedimientos para la predicción de una respuesta contra el cáncer
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
EP2785375B1
(en)
|
2011-11-28 |
2020-07-22 |
Merck Patent GmbH |
Anti-pd-l1 antibodies and uses thereof
|
|
CA2867434C
(en)
|
2012-06-07 |
2021-10-12 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
EP3406594A1
(en)
|
2012-12-07 |
2018-11-28 |
Merck Sharp & Dohme Corp. |
Biocatalytic transamination process
|
|
EP2928473B1
(en)
|
2012-12-07 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Regioselective n-2 arylation of indazoles
|
|
WO2014138101A1
(en)
|
2013-03-04 |
2014-09-12 |
Board Of Regents, The University Of Texas System |
Gene signature to predict homologous recombination (hr) deficient cancer
|
|
AR095363A1
(es)
|
2013-03-15 |
2015-10-14 |
Genentech Inc |
Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
|
|
HRP20210122T1
(hr)
|
2013-05-02 |
2021-04-16 |
Anaptysbio, Inc. |
Protutijela usmjerena protiv programirane smrti-1 (pd-1)
|
|
EP4023765A1
(en)
|
2013-12-09 |
2022-07-06 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
CN105917007A
(zh)
|
2014-01-16 |
2016-08-31 |
克洛维斯肿瘤有限公司 |
Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
|
|
AU2015210886A1
(en)
*
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
WO2015184145A1
(en)
|
2014-05-28 |
2015-12-03 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
US20160160294A1
(en)
|
2014-12-08 |
2016-06-09 |
Tesaro |
Methods and materials for predicting response to niraparib
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
SG10201909173PA
(en)
|
2015-04-01 |
2019-11-28 |
Anaptysbio Inc |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
KR20170138555A
(ko)
|
2015-04-28 |
2017-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
|
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
HK1257216A1
(zh)
|
2015-08-20 |
2019-10-18 |
益普生生物制药有限公司 |
使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
|
|
CA3003422A1
(en)
|
2015-10-26 |
2017-05-04 |
Medivation Technologies Llc |
Treatment of small cell lung cancer with a parp inhibitor
|
|
EP4071174A1
(en)
|
2016-02-15 |
2022-10-12 |
AstraZeneca AB |
Methods comprising fixed intermittent dosing of cediranib
|
|
EP3478286B1
(en)
|
2016-06-29 |
2024-01-03 |
Tesaro, Inc. |
Methods of treating ovarian cancer
|
|
EP3519051B1
(en)
|
2016-09-27 |
2021-09-22 |
Beigene, Ltd. |
Treatment of cancers using combination comprising parp inhibitors
|
|
EP3666794A1
(en)
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
EP3689419A1
(en)
|
2016-11-01 |
2020-08-05 |
AnaptysBio, Inc. |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
CN110382545A
(zh)
|
2017-01-09 |
2019-10-25 |
泰萨罗公司 |
用抗pd-1抗体治疗癌症的方法
|
|
CN110382000A
(zh)
|
2017-01-09 |
2019-10-25 |
泰萨罗公司 |
用抗tim-3抗体治疗癌症的方法
|
|
EP3606523A1
(en)
|
2017-03-27 |
2020-02-12 |
Tesaro, Inc. |
Niraparib formulations
|
|
MX2019011496A
(es)
|
2017-03-27 |
2020-01-23 |
Tesaro Inc |
Composiciones de niraparib.
|
|
MA48475A
(fr)
|
2017-04-24 |
2020-03-04 |
Tesaro Inc |
Procédés de fabrication de niraparib
|
|
NZ759517A
(en)
|
2017-04-27 |
2025-02-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
TWI879716B
(zh)
|
2017-05-09 |
2025-04-11 |
美商提薩羅有限公司 |
治療癌症的組合療法
|
|
MA49144A
(fr)
|
2017-05-18 |
2020-03-25 |
Tesaro Inc |
Polythérapies pour le traitement du cancer
|
|
US20200129482A1
(en)
|
2017-06-26 |
2020-04-30 |
Abbvie Inc. |
Treatment of non-small cell lung cancer
|
|
BR112020006039A2
(pt)
|
2017-09-26 |
2020-10-06 |
Tesaro, Inc. |
formulações de niraparibe
|
|
CA3076515A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
MA50618A
(fr)
|
2017-10-06 |
2020-08-12 |
Tesaro Inc |
Polyrhérapies et leurs utilisations
|
|
KR20200105862A
(ko)
|
2017-12-27 |
2020-09-09 |
테사로, 인코포레이티드 |
암을 치료하는 방법
|
|
KR20200118117A
(ko)
|
2018-02-05 |
2020-10-14 |
테사로, 인코포레이티드 |
소아용 니라파립 제제 및 소아용 치료 방법
|
|
EA201992594A1
(ru)
|
2018-03-26 |
2020-03-20 |
Тесаро, Инк. |
Комбинированные терапии для лечения рака
|
|
US11970530B2
(en)
|
2020-08-13 |
2024-04-30 |
Astrazeneca Ab |
Methods of treating homologous recombination deficient cancer
|